Prescient Therapeutics Limited (PTX) AI Stock Analysis

• Market Cap: AU$75.71M
• Dividend Yield: N/A
• Average Volume (3M): 690.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: N/A
• EPS Growth: -13.64%
• Country: AU
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 1,051,514,500
• 10 Day Avg. Volume: 838,009
• 30 Day Avg. Volume: 690,151
• PEG Ratio: 0.45
• Price to Book (P/B): 3.11
• Price to Sales (P/S): 8.13
• P/FCF Ratio: -4.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: AU$0.09 ▲(6.25% Upside)
• Action: Reiterated
• Date: 07/07/26

Positive Factors

Revenue Growth

Sustained ~44% YoY revenue growth in 2025 indicates the company's clinical programs or collaborations are increasing top-line support. Over the next 2-6 months this trend improves financing optionality, validates program progress to partners, and reduces per-dollar R&D leverage risk.

Negative Factors

Persistent Operating Losses

The company has posted negative operating profit and net income each year, showing no near-term profitability inflection. Over 2-6 months this structural loss profile necessitates ongoing external funding, raises dilution risk, and constrains strategic choices like trial expansion or larger commercial investments.

Prescient Therapeutics Limited Business Overview & Revenue Model

Company Description

Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several cl...

Read more

Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several cl...

How the Company Makes Money

Prescient Therapeutics is a clinical-stage biotech and, based on publicly available information, does not have an established, recurring product-revenue base from commercialized drugs. The company’s ability to generate cash is therefore primarily ...

Read more

Prescient Therapeutics is a clinical-stage biotech and, based on publicly available information, does not have an established, recurring product-revenue base from commercialized drugs. The company’s ability to generate cash is therefore primarily ...

Prescient Therapeutics Limited Financial Statement Overview

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	3.11M	4.36M	3.71M	2.43M	1.89M	1.19M
Gross Profit	3.11M	4.36M	3.71M	2.43M	1.89M	1.19M
EBITDA	-10.06M	-7.54M	-7.19M	-7.46M	-6.86M	-5.32M
Net Income	-8.86M	-7.32M	-8.24M	-7.00M	-5.12M	-4.15M
Balance Sheet
Total Assets	18.48M	14.56M	20.39M	28.11M	17.62M	20.97M
Cash, Cash Equivalents and Short-Term Investments	9.77M	6.93M	14.51M	21.92M	12.28M	16.12M
Total Debt	495.89K	0.00	330.49K	0.00	0.00	165.83K
Total Liabilities	1.51M	3.17M	2.33M	2.03M	856.01K	539.68K
Stockholders Equity	16.97M	11.39M	18.07M	26.08M	16.76M	20.43M
Cash Flow
Free Cash Flow	-8.00M	-7.24M	-7.40M	-6.19M	-4.32M	-3.97M
Operating Cash Flow	-8.00M	-7.24M	-7.40M	-6.19M	-4.31M	-3.97M
Investing Cash Flow	2.00M	4.00M	12.00M	-16.00M	-4.43K	-2.31K
Financing Cash Flow	9.02M	-330.49K	18.15K	15.83M	428.29K	12.75M

Prescient Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PTX, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.25 is Neutral, neither overbought nor oversold. The STOCH value of 56.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PTX.

Prescient Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TLX	57 Neutral	AU$5.53B	-494.08	-1.72%	―	59.13%	-121.52%
PTX	55 Neutral	AU$75.71M	-7.43	-62.49%	―	―	-13.64%
RAD	55 Neutral	AU$67.34M	-1.24	-93.08%	―	116.02%	75.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CU6	46 Neutral	AU$899.13M	-8.57	-59.59%	―	―	-70.72%
IMU	41 Neutral	AU$43.68M	-0.44	-134.65%	―	―	62.72%
IMM	40 Underperform	AU$75.16M	-0.96	-69.20%	―	―	-73.11%